| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Human Endogenous Metabolite
|
|---|---|
| ln Vitro |
In study pertaining to life sciences, dextrin is a biochemical reagent that can be utilized as an organic compound or biological material.
|
| Toxicity/Toxicokinetics |
Toxicity Summary
It is safe at the current usage and concentration. Ingredient, concentration, and usage information can be found at: https://cir-reports.cir-safety.org |
| Additional Infomation |
Dextrin are metabolites found in or produced by Escherichia coli (K12 strain, MG1655 strain). Dextrin have also been reported to exist in Streptomyces, with relevant data available. Dextrin are a class of low-molecular-weight carbohydrates produced by the hydrolysis of starch or glycogen. They are polymer mixtures composed of D-glucose units linked by α-(1→4) or α-(1→6) glycosidic bonds.
|
| Molecular Formula |
C18H32O16
|
|---|---|
| Molecular Weight |
504.44
|
| Exact Mass |
180.063
|
| CAS # |
9004-53-9
|
| PubChem CID |
62698
|
| Appearance |
White to off-white solid powder
|
| Density |
1.7±0.1 g/cm3
|
| Boiling Point |
410.8±45.0 °C at 760 mmHg
|
| Flash Point |
202.2±28.7 °C
|
| Vapour Pressure |
0.0±2.2 mmHg at 25°C
|
| Index of Refraction |
1.635
|
| LogP |
-1.88
|
| Hydrogen Bond Donor Count |
11
|
| Hydrogen Bond Acceptor Count |
16
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
34
|
| Complexity |
641
|
| Defined Atom Stereocenter Count |
13
|
| SMILES |
C([C@@H]1[C@H]([C@@H]([C@H](C(O1)O[C@@H]2[C@H](OC([C@@H]([C@H]2O)O)O[C@@H]3[C@H](O[C@@H]([C@@H]([C@H]3O)O)O)CO)CO)O)O)O)O
|
| InChi Key |
FYGDTMLNYKFZSV-MRCIVHHJSA-N
|
| InChi Code |
InChI=1S/C18H32O16/c19-1-4-7(22)8(23)12(27)17(31-4)34-15-6(3-21)32-18(13(28)10(15)25)33-14-5(2-20)30-16(29)11(26)9(14)24/h4-29H,1-3H2/t4-,5-,6-,7-,8+,9-,10-,11-,12-,13-,14-,15-,16+,17?,18?/m1/s1
|
| Chemical Name |
(3R,4S,5S,6R)-2-[(2R,3S,4R,5R)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R,6S)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9824 mL | 9.9120 mL | 19.8240 mL | |
| 5 mM | 0.3965 mL | 1.9824 mL | 3.9648 mL | |
| 10 mM | 0.1982 mL | 0.9912 mL | 1.9824 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Link: https://clinicaltrials.gov/ct2/show/NCT06827002
Conditions:Obesity and Overweight|Appetite RegulationLink: https://clinicaltrials.gov/ct2/show/NCT06883292
Conditions:Tyrosol|Creatine|Endurance Performance|CognitionLink: https://clinicaltrials.gov/ct2/show/NCT06433037
Conditions:Subjective Cognitive Decline
Title:Benefits of Alcoholic Hangover Medicine
Status:Unknown status
updateDate:2023-11-13
Ctid:NCT06126094
Link: https://clinicaltrials.gov/ct2/show/NCT06126094
Conditions:Gastrointestinal MicrobiomeLink: https://clinicaltrials.gov/ct2/show/NCT02321579
Conditions:Liver Cirrhosis|Liver CancerLink: https://clinicaltrials.gov/ct2/show/NCT01044680
Conditions:Overweight|Metabolic Syndrome XLink: https://rctportal.mhlw.go.jp/en/detail?trial_id=jRCT1051240099
Condition:Type 2 diabetes mellitusLink: https://rctportal.mhlw.go.jp/en/detail?trial_id=UMIN000051275
Condition:Healthy Japanese subjectsLink: https://rctportal.mhlw.go.jp/en/detail?trial_id=UMIN000053172
Condition:N/A (Healthy adults)Link: https://rctportal.mhlw.go.jp/en/detail?trial_id=UMIN000043543
Condition:Healthy AdultsLink: https://rctportal.mhlw.go.jp/en/detail?trial_id=jRCTs031200103
Condition:Ulcerative colitisLink: https://rctportal.mhlw.go.jp/en/detail?trial_id=UMIN000034822
Condition:Healthy adultsLink: https://rctportal.mhlw.go.jp/en/detail?trial_id=UMIN000034627
Condition:Healthy adultsLink: https://rctportal.mhlw.go.jp/en/detail?trial_id=UMIN000030159
Condition:HealthyLink: https://rctportal.mhlw.go.jp/en/detail?trial_id=UMIN000029857
Condition:Healthy subjectsLink: https://rctportal.mhlw.go.jp/en/detail?trial_id=UMIN000027549
Condition:Healthy adultsLink: https://rctportal.mhlw.go.jp/en/detail?trial_id=UMIN000028600
Condition:Healthy volunteersLink: https://rctportal.mhlw.go.jp/en/detail?trial_id=UMIN000026885
Condition:Constipation and intestinal dysbiosisLink: https://rctportal.mhlw.go.jp/en/detail?trial_id=UMIN000024432
Condition:Prevention of viral respiratory tract infectionLink: https://rctportal.mhlw.go.jp/en/detail?trial_id=UMIN000023970
Condition:Male and female who are aged 20 years and older and who have high HbA1c levelsLink: https://rctportal.mhlw.go.jp/en/detail?trial_id=UMIN000023033
Condition:Healthy long-distance runnersLink: https://rctportal.mhlw.go.jp/en/detail?trial_id=UMIN000022122
Condition:Premenstrual syndromeLink: https://rctportal.mhlw.go.jp/en/detail?trial_id=UMIN000022015
Condition:Healthy adultLink: https://rctportal.mhlw.go.jp/en/detail?trial_id=UMIN000021975
Condition:Healthy adultsLink: https://rctportal.mhlw.go.jp/en/detail?trial_id=UMIN000021352
Condition:Healthy adultLink: https://rctportal.mhlw.go.jp/en/detail?trial_id=UMIN000019451
Condition:Healthy adultsLink: https://rctportal.mhlw.go.jp/en/detail?trial_id=UMIN000018958
Condition:Healthy adultsLink: https://rctportal.mhlw.go.jp/en/detail?trial_id=UMIN000018447
Condition:Healthy adultLink: https://rctportal.mhlw.go.jp/en/detail?trial_id=UMIN000018446
Condition:Healthy adultLink: https://rctportal.mhlw.go.jp/en/detail?trial_id=UMIN000017949
Condition:Healthy adultLink: https://rctportal.mhlw.go.jp/en/detail?trial_id=UMIN000017756
Condition:Healthy adultLink: https://rctportal.mhlw.go.jp/en/detail?trial_id=UMIN000003186
Condition:DiabetesProducts are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
